

D Lynne Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8330298/publications.pdf>

Version: 2024-02-01

26
papers

1,195
citations

516561

16
h-index

580701

25
g-index

26
all docs

26
docs citations

26
times ranked

1709
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging CAR T Cell Strategies for the Treatment of AML. <i>Cancers</i> , 2022, 14, 1241.	1.7	24
2	Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. <i>Blood</i> , 2022, 139, 3605-3616.	0.6	46
3	A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2021, 138, 2433-2433.	0.6	2
4	Role of NK Cells in Cancer and Immunotherapy. <i>Onco</i> , 2021, 1, 158-175.	0.2	3
5	Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2139-2145.	2.0	14
6	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	67
7	Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2018, 24, 1114-1123.	3.2	25
8	Targeting myeloid-derived suppressor cells for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1181-1195.	2.0	95
9	Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. <i>BMC Cancer</i> , 2018, 18, 187.	1.1	16
10	Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2015, 6, 18905-18920.	0.8	30
11	The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. <i>Molecular Pharmacology</i> , 2015, 87, 996-1005.	1.0	20
12	A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance. <i>Cancer Research</i> , 2013, 73, 6484-6493.	0.4	64
13	Phase I/II Trial of Nonpegylated Liposomal Doxorubicin, Cyclophosphamide, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 59-64.	1.4	24
14	Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1712-1719.	0.8	60
15	Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. <i>Blood</i> , 2005, 105, 1310-1318.	0.6	62
16	Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. <i>International Journal of Cancer</i> , 2003, 104, 603-610.	2.3	146
17	Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. <i>International Journal of Cancer</i> , 2003, 106, 528-533.	2.3	12
18	Human Herpesvirus-8-Transformed Endothelial Cells Have Functionally Activated Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor. <i>American Journal of Pathology</i> , 2002, 160, 23-29.	1.9	93

#	ARTICLE	IF	CITATIONS
19	Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. <i>Blood</i> , 2001, 98, 1904-1913.	0.6	312
20	Paclitaxel Induces Apoptosis in AIDS-Related Kaposi's Sarcoma Cells. <i>Sarcoma</i> , 2000, 4, 37-45.	0.7	11
21	Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. <i>Current Opinion in Oncology</i> , 1998, 10, 413-421.	1.1	27
22	Human renin 5'-flanking DNA to nucleotide -2750. <i>DNA Sequence</i> , 1995, 5, 319-321.	0.7	4
23	Function of human renin proximal promoter DNA. <i>Kidney International</i> , 1994, 46, 1516-1521.	2.6	13
24	RENIN GENE EXPRESSION IN VARIOUS TISSUES DETERMINED BY SINGLE-STEP POLYMERASE CHAIN REACTION. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1991, 18, 357-362.	0.9	18
25	Prorenin and gene activation. <i>Canadian Journal of Physiology and Pharmacology</i> , 1991, 69, 1367-1374.	0.7	7
26	Human Renin Gene: Extended Sequence of 5'-Flanking DNA and its Linkage to CAT Gene for Studies of Regulation. <i>Clinical and Experimental Hypertension</i> , 1988, 10, 1309-1311.	0.3	0